Cefiderocol protects against cytokine- and endotoxin-induced disruption of vascular endothelial cell integrity in an in vitro experimental model
The severe course of bloodstream infections with Gram-negative bacilli can lead to organ dysfunctions and compromise the integrity of the vascular barrier, which are the hallmarks of sepsis. This study aimed to investigate the potential effect of cefiderocol on the barrier function of vascular endot...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
26 April 2022
|
| In: |
Antibiotics
Year: 2022, Jahrgang: 11, Heft: 5, Pages: 1-6 |
| ISSN: | 2079-6382 |
| DOI: | 10.3390/antibiotics11050581 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/antibiotics11050581 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2079-6382/11/5/581 
|
| Verfasserangaben: | Dagmar Hildebrand, Jana Böhringer, Eva Körner, Ute Chiriac, Sandra Förmer, Aline Sähr, Torsten Hoppe-Tichy, Klaus Heeg and Dennis Nurjadi |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1808679288 | ||
| 003 | DE-627 | ||
| 005 | 20230426090944.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220630s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/antibiotics11050581 |2 doi | |
| 035 | |a (DE-627)1808679288 | ||
| 035 | |a (DE-599)KXP1808679288 | ||
| 035 | |a (OCoLC)1341463276 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hildebrand, Dagmar |d 1979- |e VerfasserIn |0 (DE-588)1013137892 |0 (DE-627)704967073 |0 (DE-576)346073596 |4 aut | |
| 245 | 1 | 0 | |a Cefiderocol protects against cytokine- and endotoxin-induced disruption of vascular endothelial cell integrity in an in vitro experimental model |c Dagmar Hildebrand, Jana Böhringer, Eva Körner, Ute Chiriac, Sandra Förmer, Aline Sähr, Torsten Hoppe-Tichy, Klaus Heeg and Dennis Nurjadi |
| 264 | 1 | |c 26 April 2022 | |
| 300 | |e Supplementary material | ||
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.06.2022 | ||
| 520 | |a The severe course of bloodstream infections with Gram-negative bacilli can lead to organ dysfunctions and compromise the integrity of the vascular barrier, which are the hallmarks of sepsis. This study aimed to investigate the potential effect of cefiderocol on the barrier function of vascular endothelial cells (vECs) in an in vitro experimental set-up. Human umbilical vein cells (HUVECs), co-cultured with erythrocyte-depleted whole blood for up to 48 h, were activated with tumor necrosis factor-alpha (TNF-α) or lipopolysaccharide (LPS) to induce endothelial damage in the absence or presence of cefiderocol (concentrations of 10, 40 and 70 mg/L). The endothelial integrity was quantified using transendothelial electrical resistance (TEER) measurement, performed at 0, 3, 24 and 48 h after stimulation. Stimulation with TNF-α and LPS increased the endothelial permeability assessed by TEER at 24 and 48 h of co-culture. Furthermore, cefiderocol reduces interleukin-6 (IL-6), interleukin-1β (IL-1β) and TNF-α release in peripheral blood mononuclear cells (PBMCs) following LPS stimulation in a dose-dependent manner. Collectively, the data suggest that cefiderocol may have an influence on the cellular immune response and might support the maintenance of vEC integrity during inflammation associated with infection with Gram-negative bacteria, which warrants further investigations. | ||
| 650 | 4 | |a beta-lactam antibiotic | |
| 650 | 4 | |a cefiderocol | |
| 650 | 4 | |a endothelial barrier | |
| 650 | 4 | |a vascular leakage | |
| 700 | 1 | |a Böhringer, Jana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Körner, Eva-Maria |d 1985- |e VerfasserIn |0 (DE-588)1048708217 |0 (DE-627)781108659 |0 (DE-576)403023572 |4 aut | |
| 700 | 1 | |a Chiriac, Ute |e VerfasserIn |0 (DE-588)1196234787 |0 (DE-627)1678100854 |4 aut | |
| 700 | 1 | |a Förmer, Sandra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sähr, Aline |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoppe-Tichy, Torsten |e VerfasserIn |0 (DE-588)1095801376 |0 (DE-627)856418919 |0 (DE-576)467814597 |4 aut | |
| 700 | 1 | |a Heeg, Klaus |d 1956- |e VerfasserIn |0 (DE-588)133238369 |0 (DE-627)539308587 |0 (DE-576)299716805 |4 aut | |
| 700 | 1 | |a Nurjadi, Dennis |d 1983- |e VerfasserIn |0 (DE-588)1023024675 |0 (DE-627)717348202 |0 (DE-576)366276832 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antibiotics |d Basel : MDPI, 2012 |g 11(2022), 5, Artikel-ID 581, Seite 1-6 |h Online-Ressource |w (DE-627)726120596 |w (DE-600)2681345-2 |w (DE-576)371374081 |x 2079-6382 |7 nnas |a Cefiderocol protects against cytokine- and endotoxin-induced disruption of vascular endothelial cell integrity in an in vitro experimental model |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:5 |g elocationid:581 |g pages:1-6 |g extent:6 |a Cefiderocol protects against cytokine- and endotoxin-induced disruption of vascular endothelial cell integrity in an in vitro experimental model |
| 856 | 4 | 0 | |u https://doi.org/10.3390/antibiotics11050581 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2079-6382/11/5/581 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220630 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1023024675 |a Nurjadi, Dennis |m 1023024675:Nurjadi, Dennis |d 50000 |e 50000PN1023024675 |k 0/50000/ |p 9 |y j | ||
| 998 | |g 133238369 |a Heeg, Klaus |m 133238369:Heeg, Klaus |d 50000 |e 50000PH133238369 |k 0/50000/ |p 8 | ||
| 998 | |g 1095801376 |a Hoppe-Tichy, Torsten |m 1095801376:Hoppe-Tichy, Torsten |d 910000 |e 910000PH1095801376 |k 0/910000/ |p 7 | ||
| 998 | |g 1196234787 |a Chiriac, Ute |m 1196234787:Chiriac, Ute |d 140000 |e 140000PC1196234787 |k 0/140000/ |p 4 | ||
| 998 | |g 1048708217 |a Körner, Eva-Maria |m 1048708217:Körner, Eva-Maria |d 910000 |e 910000PK1048708217 |k 0/910000/ |p 3 | ||
| 998 | |g 1013137892 |a Hildebrand, Dagmar |m 1013137892:Hildebrand, Dagmar |d 910000 |d 911700 |d 50000 |e 910000PH1013137892 |e 911700PH1013137892 |e 50000PH1013137892 |k 0/910000/ |k 1/910000/911700/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1808679288 |e 4159275311 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 30.06.2022"],"recId":"1808679288","person":[{"display":"Hildebrand, Dagmar","given":"Dagmar","role":"aut","roleDisplay":"VerfasserIn","family":"Hildebrand"},{"family":"Böhringer","given":"Jana","role":"aut","roleDisplay":"VerfasserIn","display":"Böhringer, Jana"},{"family":"Körner","display":"Körner, Eva-Maria","roleDisplay":"VerfasserIn","role":"aut","given":"Eva-Maria"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Ute","display":"Chiriac, Ute","family":"Chiriac"},{"display":"Förmer, Sandra","roleDisplay":"VerfasserIn","role":"aut","given":"Sandra","family":"Förmer"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Aline","display":"Sähr, Aline","family":"Sähr"},{"display":"Hoppe-Tichy, Torsten","roleDisplay":"VerfasserIn","role":"aut","given":"Torsten","family":"Hoppe-Tichy"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Klaus","display":"Heeg, Klaus","family":"Heeg"},{"family":"Nurjadi","display":"Nurjadi, Dennis","role":"aut","roleDisplay":"VerfasserIn","given":"Dennis"}],"language":["eng"],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"26 April 2022"}],"name":{"displayForm":["Dagmar Hildebrand, Jana Böhringer, Eva Körner, Ute Chiriac, Sandra Förmer, Aline Sähr, Torsten Hoppe-Tichy, Klaus Heeg and Dennis Nurjadi"]},"id":{"eki":["1808679288"],"doi":["10.3390/antibiotics11050581"]},"physDesc":[{"noteAccMat":"Supplementary material","extent":"6 S."}],"relHost":[{"id":{"zdb":["2681345-2"],"eki":["726120596"],"issn":["2079-6382"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.2012 -"],"part":{"pages":"1-6","year":"2022","extent":"6","text":"11(2022), 5, Artikel-ID 581, Seite 1-6","issue":"5","volume":"11"},"recId":"726120596","note":["Gesehen am 12.09.12"],"language":["eng"],"disp":"Cefiderocol protects against cytokine- and endotoxin-induced disruption of vascular endothelial cell integrity in an in vitro experimental modelAntibiotics","origin":[{"publisher":"MDPI","dateIssuedDisp":"2012-","dateIssuedKey":"2012","publisherPlace":"Basel"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"open access journal","title_sort":"Antibiotics","title":"Antibiotics"}]}],"title":[{"title":"Cefiderocol protects against cytokine- and endotoxin-induced disruption of vascular endothelial cell integrity in an in vitro experimental model","title_sort":"Cefiderocol protects against cytokine- and endotoxin-induced disruption of vascular endothelial cell integrity in an in vitro experimental model"}]} | ||
| SRT | |a HILDEBRANDCEFIDEROCO2620 | ||